Author:
Marsh Kevin,Lanitis Tereza,Neasham David,Orfanos Panagiotis,Caro Jaime
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference63 articles.
1. Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy: report of the ISPOR risk-benefit management working group. Value Health J Int Soc Pharmacoecon Outcomes Res. 2010;13(5):657–66.
2. Garrison LP. Regulatory benefit-risk assessment and comparative effectiveness research: strangers, bedfellows or strange bedfellows? Pharmacoeconomics. 2010;28(10):855–65.
3. The future of drug safety: promoting and protecting the health of the public. Institute of Medicine, 2006.
4. Food and Drug Administration (FDA). PDUFA reauthorization performance goals and procedures fiscal years 2013 through 2017. http://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm270412.pdf . Accessed 30 April 2013.
5. European Medicines Agency (EMA). Report of the CHMP working group on benefit-risk assessment models and methods; 2007.
Cited by
195 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献